Sotera Health (SHC) Financials

$13.01 +0.63 (+5.09%)

As of 11:35 AM Eastern

Annual Income Statements for Sotera Health

This table shows Sotera Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-21	-39	117	-375	51	44
Consolidated Net Income / (Loss)	-20	-37	117	-375	86	44
Net Income / (Loss) Continuing Operations	-20	-37	117	-375	86	44
Total Pre-Tax Income	-0.92	-39	176	-243	106	114
Total Operating Income	184	206	257	248	277	298
Total Gross Profit	395	444	519	557	577	602
Total Revenue	778	818	931	0.00	1,049	1,100
Operating Revenue	778	818	931	-	1,049	1,100
Total Cost of Revenue	383	375	413	447	472	498
Operating Cost of Revenue	383	375	413	56	472	498
Total Operating Expenses	212	238	262	246	300	305
Selling, General & Admin Expense	147	179	198	246	237	243
Amortization Expense	59	59	64	-	64	62
Total Other Income / (Expense), net	-185	-245	-81	-83	-136	-184
Interest Expense	30	44	21	-	0.00	24
Interest & Investment Income	-158	-215	-74	-90	-143	-165
Other Income / (Expense), net	3.38	15	14	6.30	7.21	5.11
Income Tax Expense	20	-1.37	59	-9.54	55	69
Basic Earnings per Share	($0.09)	($0.16)	$0.41	($0.83)	$0.18	$0.16
Weighted Average Basic Shares Outstanding	232.40M	237.70M	279.23M	280.10M	281.01M	282.78M
Diluted Earnings per Share	($0.09)	($0.16)	$0.41	($0.83)	$0.18	$0.16
Weighted Average Diluted Shares Outstanding	232.40M	237.70M	279.38M	280.10M	283.22M	284.91M
Weighted Average Basic & Diluted Shares Outstanding	-	-	282.93M	282.42M	282.83M	283.47M

This table shows Sotera Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	25	-462	2.84	24	-14	39	6.32	8.75	17	12
Consolidated Net Income / (Loss)	25	-462	2.84	24	-14	74	6.32	8.75	17	12
Net Income / (Loss) Continuing Operations	25	-462	2.84	24	-14	74	6.32	8.75	17	12
Total Pre-Tax Income	42	-379	5.40	34	0.47	66	11	15	43	45
Total Operating Income	63	60	33	63	76	104	53	77	81	87
Total Gross Profit	136	142	112	140	146	180	127	153	158	164
Total Revenue	249	-752	221	255	263	310	248	277	285	290
Operating Revenue	249	-	221	255	263	310	248	277	285	290
Total Cost of Revenue	113	110	109	116	117	130	121	124	127	126
Operating Cost of Revenue	113	-281	109	116	117	130	121	124	127	126
Total Operating Expenses	73	19	78	76	70	76	74	76	78	77
Selling, General & Admin Expense	57	66	62	60	54	60	58	61	62	62
Amortization Expense	16	-	16	16	16	16	16	15	16	15
Total Other Income / (Expense), net	-21	-31	-28	-29	-76	-3.35	-42	-62	-38	-42
Interest & Investment Income	-23	-32	-29	-31	-41	-43	-42	-40	-42	-41
Other Income / (Expense), net	2.25	1.60	0.91	2.01	-35	39	-0.39	2.13	3.89	-0.52
Income Tax Expense	17	-59	2.56	11	14	27	4.69	6.39	26	33
Basic Earnings per Share	$0.09	($1.14)	$0.01	$0.08	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05
Weighted Average Basic Shares Outstanding	280.14M	280.10M	280.69M	280.89M	281.11M	281.01M	281.91M	282.89M	283.06M	282.78M
Diluted Earnings per Share	$0.09	($1.14)	$0.01	$0.08	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05
Weighted Average Diluted Shares Outstanding	280.17M	280.10M	282.98M	283.15M	281.11M	283.22M	284.06M	284.54M	285.56M	284.91M
Weighted Average Basic & Diluted Shares Outstanding	282.11M	282.42M	282.52M	282.62M	282.62M	282.83M	283.07M	283.21M	283.24M	283.47M

This table details how cash moves in and out of Sotera Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-34	39	4.47	289	-95	-23
Net Cash From Operating Activities	149	121	282	278	-148	224
Net Cash From Continuing Operating Activities	149	121	282	278	-148	224
Net Income / (Loss) Continuing Operations	-20	-37	117	-234	51	44
Consolidated Net Income / (Loss)	-20	-37	117	-234	51	44
Depreciation Expense	67	63	64	64	77	84
Amortization Expense	88	92	93	87	90	87
Non-Cash Adjustments To Reconcile Net Income	42	41	25	430	-337	4.88
Changes in Operating Assets and Liabilities, net	-27	-38	-18	-70	-29	4.01
Net Cash From Investing Activities	-57	-159	-160	-182	-215	-179
Net Cash From Continuing Investing Activities	-57	-159	-160	-182	-215	-179
Purchase of Property, Plant & Equipment	-57	-54	-102	-182	-215	-179
Other Investing Activities, net	0.00	0.00	-0.70	0.03	0.07	0.07
Net Cash From Financing Activities	-126	73	-117	198	266	-51
Net Cash From Continuing Financing Activities	-126	73	-117	198	266	-51
Repayment of Debt	-2,579	-1,199	-107	-1.85	-230	-2,299
Issuance of Debt	3,145	150	0.00	200	500	2,259
Other Financing Activities, net	0.00	0.00	-1.43	-0.39	-4.09	-11
Effect of Exchange Rate Changes	0.49	4.11	0.04	-4.46	2.04	-17
Cash Interest Paid	151	211	59	76	174	180
Cash Income Taxes Paid	45	24	52	75	50	66

This table details how cash moves in and out of Sotera Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	24	231	264	-390	-18	49	-39	-15	61	-30
Net Cash From Operating Activities	68	102	34	-337	42	113	9.70	61	97	56
Net Cash From Continuing Operating Activities	68	102	34	-337	42	113	9.70	61	97	56
Net Income / (Loss) Continuing Operations	25	-320	2.84	24	-14	39	6.32	8.75	17	12
Consolidated Net Income / (Loss)	25	-320	2.84	24	-14	39	6.32	8.75	17	12
Depreciation Expense	16	17	19	19	18	21	20	20	23	21
Amortization Expense	22	21	23	23	23	23	23	22	21	21
Non-Cash Adjustments To Reconcile Net Income	-3.81	416	7.33	-396	41	11	-32	31	11	-4.80
Changes in Operating Assets and Liabilities, net	8.97	-32	-18	-5.50	-26	20	-7.84	-20	25	6.60
Net Cash From Investing Activities	-39	-72	-45	-53	-52	-65	-35	-42	-36	-66
Net Cash From Continuing Investing Activities	-39	-72	-45	-53	-52	-65	-35	-42	-36	-66
Purchase of Property, Plant & Equipment	-39	-72	-45	-53	-52	-65	-35	-42	-36	-66
Net Cash From Financing Activities	-0.40	199	274	-0.71	-3.45	-3.79	-12	-29	-2.65	-6.55
Net Cash From Continuing Financing Activities	-0.40	199	274	-0.71	-3.45	-3.79	-12	-29	-2.65	-6.55
Repayment of Debt	-0.40	-0.36	-226	-0.71	-3.45	0.30	-5.21	-2,289	-2.65	-2.12
Other Financing Activities, net	-	-	0.00	-	-	-4.09	-6.74	-	-	-4.43
Effect of Exchange Rate Changes	-4.07	1.90	1.07	0.73	-4.37	4.62	-1.74	-5.02	2.28	-13
Cash Interest Paid	23	11	35	43	72	23	70	41	32	37
Cash Income Taxes Paid	19	19	14	14	15	7.62	9.84	18	15	23

This table presents Sotera Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	2,761	2,790	3,118	3,130	3,072
Total Current Assets	315	346	645	557	526
Cash & Equivalents	102	107	395	296	277
Restricted Cash	0.01	0.01	1.08	5.25	1.62
Accounts Receivable	92	108	118	148	140
Inventories, net	34	54	37	48	49
Prepaid Expenses	65	72	81	54	51
Current Deferred & Refundable Income Taxes	22	4.64	12	5.73	6.66
Plant, Property, & Equipment, net	610	651	775	947	1,037
Total Noncurrent Assets	1,836	1,793	1,698	1,626	1,509
Goodwill	1,116	1,120	1,102	1,111	1,081
Intangible Assets	643	599	491	416	318
Noncurrent Deferred & Refundable Income Taxes	8.42	5.89	4.10	4.99	2.87
Employee Benefit Assets	0.00	5.48	36	28	43
Other Noncurrent Operating Assets	55	53	65	65	65
Total Liabilities & Shareholders' Equity	2,761	2,790	3,118	3,130	3,072
Total Liabilities	2,307	2,203	2,767	2,687	2,667
Total Current Liabilities	141	161	792	231	191
Short-Term Debt	-	9.29	205	11	20
Accounts Payable	52	73	74	71	55
Accrued Expenses	61	62	490	122	90
Current Deferred Revenue	6.06	8.67	12	13	15
Current Deferred & Payable Income Tax Liabilities	10	6.70	5.87	4.15	7.56
Other Current Liabilities	11	1.78	4.62	8.77	2.92
Total Noncurrent Liabilities	2,152	2,042	1,976	2,456	2,476
Long-Term Debt	1,825	1,744	1,747	2,224	2,208
Capital Lease Obligations	-	41	57	64	95
Asset Retirement Reserve & Litigation Obligation	45	42	43	48	49
Noncurrent Deferred Revenue	21	21	19	19	17
Noncurrent Deferred & Payable Income Tax Liabilities	122	135	68	64	70
Noncurrent Employee Benefit Liabilities	48	11	7.91	8.44	7.86
Other Noncurrent Operating Liabilities	91	49	34	29	29
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	455	586	350	444	405
Total Preferred & Common Equity	452	586	350	444	405
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	452	586	350	444	405
Common Stock	1,169	1,175	1,192	1,218	1,247
Retained Earnings	-589	-472	-706	-654	-610
Treasury Stock	-34	-34	-30	-27	-23
Accumulated Other Comprehensive Income / (Loss)	-94	-84	-107	-93	-208

This table presents Sotera Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	2,811	3,414	3,075	3,037	3,060	3,058	3,149
Total Current Assets	421	924	547	520	487	498	564
Cash & Equivalents	164	648	263	245	261	246	307
Restricted Cash	0.99	12	7.79	7.58	1.69	1.67	1.74
Accounts Receivable	112	109	117	118	111	124	130
Inventories, net	37	47	42	38	51	58	54
Prepaid Expenses	82	87	91	84	54	57	57
Current Deferred & Refundable Income Taxes	25	20	26	27	8.29	12	14
Plant, Property, & Equipment, net	704	816	859	884	979	995	1,026
Total Noncurrent Assets	1,685	1,674	1,669	1,633	1,593	1,566	1,559
Goodwill	1,092	1,103	1,110	1,101	1,103	1,098	1,105
Intangible Assets	504	472	456	429	390	368	352
Noncurrent Deferred & Refundable Income Taxes	5.09	4.17	4.16	4.04	4.88	4.75	4.95
Employee Benefit Assets	9.86	37	39	39	30	31	33
Other Noncurrent Operating Assets	74	58	59	59	65	64	65
Total Liabilities & Shareholders' Equity	2,811	3,414	3,075	3,037	3,060	3,058	3,149
Total Liabilities	2,204	3,053	2,657	2,659	2,630	2,635	2,679
Total Current Liabilities	140	600	200	201	152	170	196
Short-Term Debt	7.72	20	12	12	10	16	20
Accounts Payable	61	62	56	57	62	64	71
Accrued Expenses	57	497	103	106	62	69	83
Current Deferred Revenue	5.35	15	14	13	13	13	11
Current Deferred & Payable Income Tax Liabilities	7.35	4.59	5.73	4.14	4.51	4.41	8.34
Other Current Liabilities	2.12	2.11	9.40	8.65	1.49	2.77	2.82
Total Noncurrent Liabilities	2,064	2,453	2,456	2,459	2,478	2,465	2,483
Long-Term Debt	1,747	2,222	2,222	2,223	2,225	2,214	2,211
Capital Lease Obligations	55	82	61	84	91	94	98
Asset Retirement Reserve & Litigation Obligation	44	43	44	44	48	48	49
Noncurrent Deferred Revenue	19	19	19	18	18	18	18
Noncurrent Deferred & Payable Income Tax Liabilities	152	63	68	69	60	54	64
Noncurrent Employee Benefit Liabilities	10	7.86	8.01	7.76	8.24	8.18	8.22
Other Noncurrent Operating Liabilities	38	15	33	12	28	30	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	607	361	418	377	429	423	470
Total Preferred & Common Equity	607	361	418	377	429	423	470
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	607	361	418	377	429	423	470
Common Stock	1,189	1,198	1,206	1,213	1,223	1,232	1,242
Retained Earnings	-386	-703	-679	-693	-648	-639	-622
Treasury Stock	-33	-29	-29	-28	-26	-25	-25
Accumulated Other Comprehensive Income / (Loss)	-164	-105	-79	-114	-120	-145	-125

This table displays calculated financial ratios and metrics derived from Sotera Health's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	5.12%	13.85%	-100.00%	0.00%	4.88%
EBITDA Growth	0.00%	9.90%	13.78%	-5.09%	11.09%	5.04%
EBIT Growth	0.00%	18.01%	22.63%	-5.89%	11.49%	6.63%
NOPAT Growth	0.00%	12.21%	18.66%	1.59%	-22.88%	-13.45%
Net Income Growth	0.00%	-83.55%	412.40%	-420.57%	123.01%	-48.60%
EPS Growth	0.00%	-77.78%	356.25%	-302.44%	121.69%	-11.11%
Operating Cash Flow Growth	0.00%	-19.09%	133.48%	-1.27%	-153.15%	251.74%
Free Cash Flow Firm Growth	0.00%	0.00%	104.20%	456.08%	-172.38%	131.16%
Invested Capital Growth	0.00%	0.00%	3.94%	-13.29%	24.33%	0.37%
Revenue Q/Q Growth	0.00%	0.00%	2.69%	-100.00%	5.92%	-1.79%
EBITDA Q/Q Growth	0.00%	0.00%	4.23%	-3.38%	1,123.75%	-4.70%
EBIT Q/Q Growth	0.00%	0.00%	6.72%	-4.71%	238.05%	-6.69%
NOPAT Q/Q Growth	0.00%	0.00%	53.03%	8.52%	-17.74%	-29.82%
Net Income Q/Q Growth	0.00%	0.00%	210.35%	-407.38%	128.13%	-37.25%
EPS Q/Q Growth	0.00%	0.00%	272.73%	-293.02%	116.36%	-36.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	18.78%	14.68%	7.05%	-20.39%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	420.01%	-1,074.23%	-9.34%
Invested Capital Q/Q Growth	0.00%	0.00%	3.73%	-12.81%	-0.12%	-1.66%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	50.81%	54.22%	55.68%	0.00%	55.00%	54.73%
EBITDA Margin	43.94%	45.94%	45.91%	0.00%	42.97%	43.04%
Operating Margin	23.59%	25.18%	27.56%	0.00%	26.37%	27.05%
EBIT Margin	24.02%	26.97%	29.05%	0.00%	27.06%	27.51%
Profit (Net Income) Margin	-2.62%	-4.58%	12.57%	0.00%	8.23%	4.03%
Tax Burden Percent	2,229.80%	96.48%	66.65%	154.44%	81.47%	38.99%
Interest Burden Percent	-0.49%	-17.61%	64.94%	-95.47%	37.35%	37.62%
Effective Tax Rate	0.00%	0.00%	33.35%	0.00%	51.54%	61.01%
Return on Invested Capital (ROIC)	0.00%	13.24%	7.71%	0.00%	6.09%	4.75%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-7.85%	4.53%	0.00%	3.45%	1.20%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-29.74%	14.80%	0.00%	15.67%	5.72%
Return on Equity (ROE)	0.00%	-16.50%	22.51%	-80.20%	21.76%	10.46%
Cash Return on Invested Capital (CROIC)	0.00%	-186.76%	3.84%	22.46%	-15.60%	4.38%
Operating Return on Assets (OROA)	0.00%	7.99%	9.75%	0.00%	9.09%	9.76%
Return on Assets (ROA)	0.00%	-1.36%	4.22%	0.00%	2.76%	1.43%
Return on Common Equity (ROCE)	0.00%	-16.41%	22.46%	-80.20%	21.76%	10.46%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-8.29%	19.98%	-107.20%	19.47%	10.96%
Net Operating Profit after Tax (NOPAT)	129	144	171	174	134	116
NOPAT Margin	16.51%	17.63%	18.37%	0.00%	12.78%	10.54%
Net Nonoperating Expense Percent (NNEP)	0.00%	21.09%	3.18%	33.39%	2.64%	3.55%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	7.37%	4.89%	4.25%
Cost of Revenue to Revenue	49.19%	45.78%	44.32%	0.00%	45.00%	45.27%
SG&A Expenses to Revenue	18.95%	21.82%	21.27%	0.00%	22.56%	22.05%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.22%	29.04%	28.12%	0.00%	28.64%	27.69%
Earnings before Interest and Taxes (EBIT)	187	221	271	255	284	303
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	342	376	428	406	451	474
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.83	11.37	6.71	10.73	9.57
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.38	1.56	7.15	0.00	4.54	3.52
Price to Earnings (P/E)	0.00	0.00	57.00	0.00	92.69	87.27
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	1.75%	0.00%	1.08%	1.15%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.37	3.68	2.02	2.77	2.42
Enterprise Value to Revenue (EV/Rev)	0.00	3.65	8.95	0.00	6.44	5.38
Enterprise Value to EBITDA (EV/EBITDA)	0.00	7.96	19.50	9.76	14.99	12.50
Enterprise Value to EBIT (EV/EBIT)	0.00	13.55	30.82	15.56	23.81	19.55
Enterprise Value to NOPAT (EV/NOPAT)	0.00	20.73	48.74	22.79	50.41	51.01
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	24.79	29.62	14.26	0.00	26.41
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	97.71	8.35	0.00	55.30
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	4.01	3.06	5.74	5.18	5.74
Long-Term Debt to Equity	0.00	4.01	3.04	5.15	5.16	5.69
Financial Leverage	0.00	3.79	3.27	3.51	4.55	4.76
Leverage Ratio	0.00	6.07	5.33	6.31	7.87	7.31
Compound Leverage Factor	0.00	-1.07	3.46	-6.02	2.94	2.75
Debt to Total Capital	0.00%	80.06%	75.37%	85.15%	83.82%	85.16%
Short-Term Debt to Total Capital	0.00%	0.00%	0.39%	8.68%	0.39%	0.73%
Long-Term Debt to Total Capital	0.00%	80.06%	74.98%	76.48%	83.43%	84.43%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	19.84%	24.63%	14.85%	16.18%	14.84%
Debt to EBITDA	0.00	4.86	4.19	4.95	5.10	4.91
Net Debt to EBITDA	0.00	4.55	3.92	3.97	4.43	4.32
Long-Term Debt to EBITDA	0.00	4.86	4.17	4.44	5.07	4.86
Debt to NOPAT	0.00	12.65	10.48	11.55	17.14	20.02
Net Debt to NOPAT	0.00	11.85	9.80	9.28	14.89	17.62
Long-Term Debt to NOPAT	0.00	12.65	10.43	10.38	17.06	19.85
Altman Z-Score	0.00	0.67	2.31	0.41	1.53	1.41
Noncontrolling Interest Sharing Ratio	0.00%	0.50%	0.22%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	2.24	2.15	0.81	2.42	2.75
Quick Ratio	0.00	1.38	1.33	0.65	1.93	2.19
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-2,033	85	475	-344	107
Operating Cash Flow to CapEx	260.30%	225.36%	275.59%	152.41%	-68.72%	125.18%
Free Cash Flow to Firm to Interest Expense	0.00	-45.94	4.13	0.00	0.00	4.43
Operating Cash Flow to Interest Expense	4.94	2.72	13.61	0.00	0.00	9.28
Operating Cash Flow Less CapEx to Interest Expense	3.04	1.52	8.67	0.00	0.00	1.87
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.30	0.34	0.00	0.34	0.35
Accounts Receivable Turnover	0.00	8.92	9.32	0.00	7.88	7.64
Inventory Turnover	0.00	10.99	9.34	9.77	11.05	10.22
Fixed Asset Turnover	0.00	1.34	1.48	0.00	1.22	1.11
Accounts Payable Turnover	0.00	7.15	6.59	6.08	6.50	7.90
Days Sales Outstanding (DSO)	0.00	40.93	39.17	0.00	46.30	47.77
Days Inventory Outstanding (DIO)	0.00	33.22	39.07	37.36	33.03	35.71
Days Payable Outstanding (DPO)	0.00	51.06	55.38	60.06	56.12	46.21
Cash Conversion Cycle (CCC)	0.00	23.09	22.86	0.00	23.21	37.27
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	2,178	2,263	1,963	2,440	2,449
Invested Capital Turnover	0.00	0.75	0.42	0.00	0.48	0.45
Increase / (Decrease) in Invested Capital	0.00	2,178	86	-301	478	9.01
Enterprise Value (EV)	0.00	2,990	8,340	3,962	6,759	5,919
Market Capitalization	1,072	1,279	6,663	2,350	4,762	3,875
Book Value per Share	$0.00	$1.90	$2.07	$1.24	$1.57	$1.43
Tangible Book Value per Share	$0.00	($5.50)	($4.00)	($4.41)	($3.83)	($3.51)
Total Capital	0.00	2,279	2,380	2,359	2,742	2,728
Total Debt	0.00	1,825	1,794	2,009	2,298	2,323
Total Long-Term Debt	0.00	1,825	1,784	1,804	2,287	2,303
Net Debt	0.00	1,709	1,677	1,612	1,997	2,044
Capital Expenditures (CapEx)	57	54	102	182	215	179
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	72	87	-338	36	76
Debt-free Net Working Capital (DFNWC)	0.00	174	194	58	337	355
Net Working Capital (NWC)	0.00	174	185	-147	327	335
Net Nonoperating Expense (NNE)	149	182	54	549	48	72
Net Nonoperating Obligations (NNO)	0.00	1,723	1,677	1,612	1,997	2,044
Total Depreciation and Amortization (D&A)	155	155	157	151	167	171
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	8.80%	9.36%	0.00%	3.40%	6.91%
Debt-free Net Working Capital to Revenue	0.00%	21.32%	20.84%	0.00%	32.15%	32.25%
Net Working Capital to Revenue	0.00%	21.32%	19.84%	0.00%	31.12%	30.45%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.41	($0.83)	$0.18	$0.16
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	279.23M	280.10M	281.01M	282.78M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.41	($0.83)	$0.18	$0.16
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	279.38M	280.10M	283.22M	284.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	282.93M	282.42M	282.83M	283.47M
Normalized Net Operating Profit after Tax (NOPAT)	133	144	171	174	194	208
Normalized NOPAT Margin	17.03%	17.63%	18.37%	0.00%	18.46%	18.93%
Pre Tax Income Margin	-0.12%	-4.75%	18.86%	0.00%	10.10%	10.35%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	6.20	4.99	13.08	0.00	0.00	12.53
NOPAT to Interest Expense	4.26	3.26	8.27	0.00	0.00	4.80
EBIT Less CapEx to Interest Expense	4.30	3.78	8.14	0.00	0.00	5.12
NOPAT Less CapEx to Interest Expense	2.36	2.05	3.33	0.00	0.00	-2.61
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	-3,383.94%	0.00%	7.19%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3,383.94%	-90.69%	7.19%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sotera Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.97%	-411.75%	-6.83%	-4.26%	5.82%	141.25%	12.51%	8.35%	8.47%	-6.46%
EBITDA Growth	-1.73%	-12.48%	-18.70%	-2.93%	-20.67%	87.23%	26.45%	13.12%	57.58%	-31.28%
EBIT Growth	-0.25%	-16.92%	-38.44%	-9.13%	-37.20%	132.04%	54.02%	21.03%	105.36%	-39.56%
NOPAT Growth	-13.94%	3.45%	-51.52%	-4.67%	-5,960.81%	45.48%	73.90%	3.03%	101.45%	-61.02%
Net Income Growth	-8.58%	-1,382.35%	-90.72%	-22.70%	-154.44%	115.96%	122.48%	-62.77%	224.44%	-83.28%
EPS Growth	-10.00%	-1,050.00%	-90.91%	-27.27%	-155.56%	112.28%	100.00%	-62.50%	220.00%	-64.29%
Operating Cash Flow Growth	-16.26%	53.62%	-32.21%	-677.42%	-38.26%	10.99%	-71.36%	118.21%	132.87%	-50.75%
Free Cash Flow Firm Growth	98.54%	861.00%	505.29%	-196.71%	-7,606.69%	-221.41%	-232.50%	89.29%	99.36%	103.57%
Invested Capital Growth	3.16%	-13.29%	-13.34%	5.95%	8.54%	24.33%	23.06%	2.23%	1.94%	0.37%
Revenue Q/Q Growth	-6.73%	-402.41%	-12.32%	15.73%	3.09%	17.88%	-20.00%	11.45%	3.21%	1.66%
EBITDA Q/Q Growth	-6.50%	-3.22%	124.56%	41.18%	-23.59%	128.42%	-36.83%	26.30%	6.44%	-0.39%
EBIT Q/Q Growth	-8.81%	-5.62%	109.90%	90.28%	-36.98%	248.74%	-51.27%	49.53%	6.93%	2.64%
NOPAT Q/Q Growth	-16.52%	11.61%	-58.32%	145.50%	-5,232.20%	102.77%	-50.18%	45.45%	-27.91%	-25.38%
Net Income Q/Q Growth	-17.52%	-1,939.80%	100.89%	727.34%	-158.10%	639.39%	-83.65%	38.45%	94.17%	-27.50%
EPS Q/Q Growth	-18.18%	-1,366.67%	100.88%	700.00%	-162.50%	380.00%	-85.71%	50.00%	100.00%	-16.67%
Operating Cash Flow Q/Q Growth	16.28%	50.38%	-66.77%	-1,093.70%	112.43%	170.31%	-91.43%	531.97%	58.99%	-42.83%
Free Cash Flow Firm Q/Q Growth	1.74%	1,199.28%	-3.93%	-128.59%	-2,452.32%	82.68%	-4.85%	97.69%	-51.57%	197.27%
Invested Capital Q/Q Growth	-2.39%	-12.81%	3.18%	20.66%	-0.01%	-0.12%	2.13%	0.23%	-0.30%	-1.66%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.69%	0.00%	50.55%	54.68%	55.47%	58.05%	51.22%	55.24%	55.36%	56.64%
EBITDA Margin	41.40%	0.00%	34.33%	41.88%	31.04%	60.14%	38.58%	43.72%	45.09%	44.18%
Operating Margin	25.41%	0.00%	15.13%	24.76%	28.92%	33.53%	21.43%	27.77%	28.20%	30.03%
EBIT Margin	26.31%	0.00%	15.54%	25.55%	15.62%	46.20%	21.27%	28.54%	29.56%	29.85%
Profit (Net Income) Margin	10.09%	0.00%	1.29%	9.21%	-5.19%	23.75%	2.55%	3.16%	5.95%	4.25%
Tax Burden Percent	59.72%	121.96%	52.61%	68.18%	-2,906.38%	112.20%	57.41%	57.81%	39.76%	27.41%
Interest Burden Percent	64.20%	-612.79%	15.76%	52.88%	1.14%	45.82%	20.87%	19.18%	50.66%	51.91%
Effective Tax Rate	40.28%	0.00%	47.39%	31.82%	3,006.38%	41.10%	42.59%	42.19%	60.24%	72.59%
Return on Invested Capital (ROIC)	6.80%	0.00%	3.60%	6.94%	-354.70%	9.41%	5.86%	7.13%	5.09%	3.70%
ROIC Less NNEP Spread (ROIC-NNEP)	6.03%	0.00%	2.73%	5.88%	-236.21%	10.10%	4.57%	5.40%	4.36%	3.13%
Return on Net Nonoperating Assets (RNNOA)	17.58%	0.00%	9.13%	20.60%	-890.40%	45.91%	21.52%	26.31%	21.01%	14.91%
Return on Equity (ROE)	24.38%	-80.20%	12.73%	27.54%	-1,245.10%	55.33%	27.39%	33.44%	26.10%	18.62%
Cash Return on Invested Capital (CROIC)	4.12%	22.46%	21.62%	0.70%	-1.25%	-15.60%	-14.23%	3.25%	4.79%	4.38%
Operating Return on Assets (OROA)	9.41%	0.00%	4.91%	8.43%	5.29%	15.52%	7.08%	10.22%	10.71%	10.59%
Return on Assets (ROA)	3.61%	0.00%	0.41%	3.04%	-1.76%	7.98%	0.85%	1.13%	2.16%	1.51%
Return on Common Equity (ROCE)	24.38%	-80.20%	12.73%	27.54%	-1,245.10%	55.33%	27.39%	33.44%	26.10%	18.62%
Return on Equity Simple (ROE_SIMPLE)	20.13%	0.00%	-72.38%	-64.12%	-81.34%	0.00%	12.78%	9.48%	15.05%	0.00%
Net Operating Profit after Tax (NOPAT)	38	42	18	43	-2,212	61	31	44	32	24
NOPAT Margin	15.17%	0.00%	7.96%	16.88%	-840.38%	19.75%	12.30%	16.05%	11.21%	8.23%
Net Nonoperating Expense Percent (NNEP)	0.77%	30.62%	0.88%	1.06%	-118.49%	-0.69%	1.30%	1.74%	0.73%	0.57%
Return On Investment Capital (ROIC_SIMPLE)	-	1.79%	-	-	-	2.23%	-	-	-	0.88%
Cost of Revenue to Revenue	45.31%	0.00%	49.45%	45.32%	44.53%	41.95%	48.78%	44.76%	44.64%	43.36%
SG&A Expenses to Revenue	22.96%	0.00%	28.07%	23.62%	20.56%	19.46%	23.45%	21.90%	21.72%	21.31%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	29.28%	0.00%	35.42%	29.92%	26.55%	24.52%	29.79%	27.47%	27.15%	26.61%
Earnings before Interest and Taxes (EBIT)	65	62	34	65	41	143	53	79	84	87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	103	100	76	107	82	187	96	121	129	128
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.18	6.71	14.01	12.72	11.22	10.73	7.90	7.95	10.06	9.57
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.94	0.00	5.12	5.45	4.27	4.54	3.15	3.06	4.22	3.52
Price to Earnings (P/E)	15.80	0.00	0.00	0.00	0.00	92.69	61.88	83.80	66.84	87.27
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.33%	0.00%	0.00%	0.00%	0.00%	1.08%	1.62%	1.19%	1.50%	1.15%
Enterprise Value to Invested Capital (EV/IC)	1.59	2.02	3.32	3.01	2.58	2.77	2.19	2.18	2.71	2.42
Enterprise Value to Revenue (EV/Rev)	3.60	0.00	6.81	7.53	6.36	6.44	5.07	4.95	6.02	5.38
Enterprise Value to EBITDA (EV/EBITDA)	8.51	9.76	0.00	0.00	0.00	14.99	12.52	12.08	13.58	12.50
Enterprise Value to EBIT (EV/EBIT)	13.37	15.56	0.00	0.00	0.00	23.81	20.41	19.33	20.81	19.55
Enterprise Value to NOPAT (EV/NOPAT)	22.31	22.79	42.08	47.73	38.65	50.41	37.46	40.34	40.82	51.01
Enterprise Value to Operating Cash Flow (EV/OCF)	14.74	14.26	25.67	0.00	0.00	0.00	0.00	24.05	23.97	26.41
Enterprise Value to Free Cash Flow (EV/FCFF)	39.15	8.35	14.25	440.72	0.00	0.00	0.00	67.74	57.18	55.30
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.98	5.74	6.44	5.49	6.14	5.18	5.42	5.49	4.95	5.74
Long-Term Debt to Equity	2.97	5.15	6.38	5.46	6.11	5.16	5.39	5.46	4.91	5.69
Financial Leverage	2.91	3.51	3.35	3.50	3.77	4.55	4.71	4.87	4.82	4.76
Leverage Ratio	4.90	6.31	6.23	5.61	5.94	7.87	8.19	7.29	7.30	7.31
Compound Leverage Factor	3.15	-38.66	0.98	2.97	0.07	3.61	1.71	1.40	3.70	3.79
Debt to Total Capital	74.89%	85.15%	86.55%	84.58%	86.00%	83.82%	84.41%	84.60%	83.20%	85.16%
Short-Term Debt to Total Capital	0.32%	8.68%	0.73%	0.45%	0.43%	0.39%	0.37%	0.58%	0.72%	0.73%
Long-Term Debt to Total Capital	74.57%	76.48%	85.82%	84.13%	85.57%	83.43%	84.05%	84.02%	82.49%	84.43%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	25.11%	14.85%	13.45%	15.42%	14.00%	16.18%	15.59%	15.40%	16.80%	14.84%
Debt to EBITDA	4.31	4.95	-118.99	-100.88	-52.64	5.10	5.34	5.16	4.69	4.91
Net Debt to EBITDA	3.91	3.97	-85.19	-89.00	-46.90	4.43	4.73	4.61	4.07	4.32
Long-Term Debt to EBITDA	4.29	4.44	-117.99	-100.34	-52.37	5.07	5.31	5.13	4.65	4.86
Debt to NOPAT	11.29	11.55	14.55	14.91	14.22	17.14	15.96	17.24	14.08	20.02
Net Debt to NOPAT	10.26	9.28	10.42	13.15	12.67	14.89	14.16	15.40	12.22	17.62
Long-Term Debt to NOPAT	11.25	10.38	14.43	14.83	14.15	17.06	15.89	17.12	13.96	19.85
Altman Z-Score	0.88	0.20	1.14	1.42	1.13	1.38	1.02	1.05	1.37	1.18
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.00	0.81	1.54	2.73	2.59	2.42	3.20	2.93	2.88	2.75
Quick Ratio	1.97	0.65	1.26	1.90	1.81	1.93	2.44	2.18	2.23	2.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-31	343	329	-94	-2,404	-416	-436	-10	-15	15
Operating Cash Flow to CapEx	173.79%	142.08%	75.27%	-633.45%	80.46%	174.50%	27.80%	146.22%	267.81%	84.59%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.43	-218.40	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.62	1,392.19	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.83	872.34	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.00	0.32	0.33	0.34	0.34	0.33	0.36	0.36	0.35
Accounts Receivable Turnover	9.56	0.00	8.82	8.23	8.61	7.88	9.78	9.11	9.02	7.64
Inventory Turnover	11.90	9.77	9.69	10.94	12.04	11.05	9.87	9.85	10.97	10.22
Fixed Asset Turnover	1.50	0.00	1.33	1.25	1.25	1.22	1.20	1.18	1.17	1.11
Accounts Payable Turnover	7.89	6.08	7.65	7.40	7.67	6.50	7.84	8.20	7.86	7.90
Days Sales Outstanding (DSO)	38.16	0.00	41.38	44.34	42.37	46.30	37.32	40.04	40.48	47.77
Days Inventory Outstanding (DIO)	30.68	37.36	37.66	33.35	30.32	33.03	36.97	37.07	33.26	35.71
Days Payable Outstanding (DPO)	46.25	60.06	47.74	49.30	47.60	56.12	46.56	44.52	46.45	46.21
Cash Conversion Cycle (CCC)	22.59	0.00	31.31	28.39	25.10	23.21	27.73	32.59	27.29	37.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,251	1,963	2,025	2,443	2,443	2,440	2,492	2,498	2,491	2,449
Invested Capital Turnover	0.45	0.00	0.45	0.41	0.42	0.48	0.48	0.44	0.45	0.45
Increase / (Decrease) in Invested Capital	69	-301	-312	137	192	478	467	54	47	9.01
Enterprise Value (EV)	3,574	3,962	6,722	7,348	6,299	6,759	5,457	5,435	6,750	5,919
Market Capitalization	1,929	2,350	5,058	5,323	4,234	4,762	3,394	3,360	4,730	3,875
Book Value per Share	$2.14	$1.24	$1.28	$1.48	$1.34	$1.57	$1.52	$1.49	$1.66	$1.43
Tangible Book Value per Share	($3.50)	($4.41)	($4.30)	($4.06)	($4.08)	($3.83)	($3.77)	($3.69)	($3.48)	($3.51)
Total Capital	2,416	2,359	2,685	2,714	2,696	2,742	2,755	2,746	2,799	2,728
Total Debt	1,809	2,009	2,324	2,296	2,318	2,298	2,326	2,323	2,329	2,323
Total Long-Term Debt	1,801	1,804	2,305	2,283	2,307	2,287	2,315	2,307	2,309	2,303
Net Debt	1,644	1,612	1,664	2,025	2,066	1,997	2,063	2,075	2,020	2,044
Capital Expenditures (CapEx)	39	72	45	53	52	65	35	42	36	66
Debt-free, Cash-free Net Working Capital (DFCFNWC)	123	-338	-317	88	78	36	82	96	80	76
Debt-free Net Working Capital (DFNWC)	288	58	343	359	331	337	345	344	388	355
Net Working Capital (NWC)	281	-147	324	346	319	327	335	328	368	335
Net Nonoperating Expense (NNE)	13	504	15	20	-2,198	-12	24	36	15	12
Net Nonoperating Obligations (NNO)	1,644	1,612	1,664	2,025	2,066	1,997	2,063	2,075	2,020	2,044
Total Depreciation and Amortization (D&A)	38	38	41	42	41	43	43	42	44	42
Debt-free, Cash-free Net Working Capital to Revenue	12.43%	0.00%	-32.10%	9.04%	7.89%	3.40%	7.63%	8.76%	7.11%	6.91%
Debt-free Net Working Capital to Revenue	29.04%	0.00%	34.75%	36.75%	33.38%	32.15%	32.03%	31.32%	34.64%	32.25%
Net Working Capital to Revenue	28.26%	0.00%	32.77%	35.48%	32.21%	31.12%	31.09%	29.87%	32.85%	30.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.09	($1.14)	$0.01	$0.08	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05
Adjusted Weighted Average Basic Shares Outstanding	280.14M	280.10M	280.69M	280.89M	281.11M	281.01M	281.91M	282.89M	283.06M	282.78M
Adjusted Diluted Earnings per Share	$0.09	($1.14)	$0.01	$0.08	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05
Adjusted Weighted Average Diluted Shares Outstanding	280.17M	280.10M	282.98M	283.15M	281.11M	283.22M	284.06M	284.54M	285.56M	284.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	282.11M	282.42M	282.52M	282.62M	282.62M	282.83M	283.07M	283.21M	283.24M	283.47M
Normalized Net Operating Profit after Tax (NOPAT)	38	42	18	43	53	61	31	44	56	61
Normalized NOPAT Margin	15.17%	0.00%	7.96%	16.88%	20.24%	19.75%	12.30%	16.05%	19.74%	21.02%
Pre Tax Income Margin	16.89%	0.00%	2.45%	13.51%	0.18%	21.17%	4.44%	5.47%	14.98%	15.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.37	1,205.66	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.90	457.25	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.58	685.81	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	-62.59	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Sotera Health's Financials

When does Sotera Health's fiscal year end?

According to the most recent income statement we have on file, Sotera Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sotera Health's net income changed over the last 5 years?

Sotera Health's net income appears to be on a downward trend, with a most recent value of $44.40 million in 2024, falling from -$20.43 million in 2019. The previous period was $86.38 million in 2023. Find out what analysts predict for Sotera Health in the coming months.

What is Sotera Health's operating income?

Sotera Health's total operating income in 2024 was $297.63 million, based on the following breakdown:

Total Gross Profit: $602.30 million
Total Operating Expenses: $304.67 million

How has Sotera Health revenue changed over the last 5 years?

Over the last 5 years, Sotera Health's total revenue changed from $778.33 million in 2019 to $1.10 billion in 2024, a change of 41.4%.

How much debt does Sotera Health have?

Sotera Health's total liabilities were at $2.67 billion at the end of 2024, a 0.7% decrease from 2023, and a 15.6% increase since 2020.

How much cash does Sotera Health have?

In the past 4 years, Sotera Health's cash and equivalents has ranged from $102.45 million in 2020 to $395.21 million in 2022, and is currently $277.24 million as of their latest financial filing in 2024.

How has Sotera Health's book value per share changed over the last 5 years?

Over the last 5 years, Sotera Health's book value per share changed from 0.00 in 2019 to 1.43 in 2024, a change of 143.0%.

Related Companies

This page (NASDAQ:SHC) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sotera Health (SHC) Financials

Frequently Asked Questions About Sotera Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sotera Health (SHC) Financials

Annual Income Statements for Sotera Health

Quarterly Income Statements for Sotera Health

Annual Cash Flow Statements for Sotera Health

Quarterly Cash Flow Statements for Sotera Health

Annual Balance Sheets for Sotera Health

Quarterly Balance Sheets for Sotera Health

Annual Metrics and Ratios for Sotera Health

Quarterly Metrics and Ratios for Sotera Health

Frequently Asked Questions About Sotera Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools